Who Buys Empagliflozin from India — 236 Importers Behind a $6.7M Market

The buyer landscape for Empagliflozin imported from India encompasses several key segments:

1. Distributors: Entities like REGENCY PHARMA LIMITED and REGENCY PHARMA LTD in Mauritius, as well as BPOST INTERNATIONAL in Belgium, function as intermediaries, purchasing large quantities to supply regional markets. Their buying behavior typically involves bulk orders to leverage economies of scale, with a focus on consistent supply chains to meet market demand.

2. Retail Chains: Companies such as VERONA PHARMACY PTE LIMITED in Singapore represent retail pharmacy chains that procure Empagliflozin to stock their outlets. Their order patterns are influenced by consumer demand, leading to regular, moderate-sized purchases to maintain inventory levels without overstocking.

3. Government Procurement: Entities like CITI BANK N.A., COLOMBO and HOTTON NATIONAL BANK PLC in Sri Lanka may be involved in facilitating government tenders or bulk purchases for public healthcare programs. This segment's buying behavior is characterized by large, infrequent orders aligned with government procurement cycles and budget allocations.

4. Re-exporters: Companies such as BPOST INTERNATIONAL EMC in Belgium may act as re-exporters, importing Empagliflozin from India to distribute it to other countries. Their order patterns are typically large and strategic, aiming to serve multiple markets efficiently.

5. Contract Manufacturers: Entities like GENERIC PHARMA S.A. in El Salvador may engage in contract manufacturing, importing active pharmaceutical ingredients (APIs) like Empagliflozin for formulation and packaging before distribution. Their purchasing behavior involves bulk procurement of APIs, followed by manufacturing processes to produce finished pharmaceutical products.

Understanding the import regulations for Empagliflozin in the top importing countries is crucial for market entry and compliance:

The demand for Empagliflozin in importing countries is driven by several factors:

1. Disease Prevalence: The rising incidence of type 2 diabetes globally has increased the need for effective management options like Empagliflozin. For instance, Mauritius reported a diabetes prevalence rate of approximately 22% in 2023, one of the highest globally, underscoring the demand for antidiabetic medications.

2. Government Healthcare Programs: Many countries have implemented national health programs focusing on non-communicable diseases, including diabetes. These programs often include the procurement of essential medicines like Empagliflozin to ensure widespread availability.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in countries like Sri Lanka and the UAE have led to increased access to medications, boosting the import and distribution of drugs such as Empagliflozin.

4. WHO Essential Medicines List Procurement: Empagliflozin's inclusion in the WHO Essential Medicines List has prompted countries to prioritize its procurement, ensuring that it is available in public healthcare facilities.

5. Tender-Based Purchasing: Government and large healthcare institutions often procure medications through tender processes, leading to bulk purchases of Empagliflozin. This approach ensures cost-effectiveness and consistent supply, contributing to the steady demand observed in the import data.

The presence of 236 buyers across 75 countries, as per TransData Nexus data, reflects a broad and sustained market opportunity for Empagliflozin, driven by these demand factors.

The buyer landscape for Empagliflozin imported from India encompasses several key segments:

1. Distributors: Entities like REGENCY PHARMA LIMITED and REGENCY PHARMA LTD in Mauritius, as well as BPOST INTERNATIONAL in Belgium, function as intermediaries, purchasing large quantities to supply regional markets. Their buying behavior typically involves bulk orders to leverage economies of scale, with a focus on consistent supply chains to meet market demand.

2. Retail Chains: Companies such as VERONA PHARMACY PTE LIMITED in Singapore represent retail pharmacy chains that procure Empagliflozin to stock their outlets. Their order patterns are influenced by consumer demand, leading to regular, moderate-sized purchases to maintain inventory levels without overstocking.

3. Government Procurement: Entities like CITI BANK N.A., COLOMBO and HOTTON NATIONAL BANK PLC in Sri Lanka may be involved in facilitating government tenders or bulk purchases for public healthcare programs. This segment's buying behavior is characterized by large, infrequent orders aligned with government procurement cycles and budget allocations.

4. Re-exporters: Companies such as BPOST INTERNATIONAL EMC in Belgium may act as re-exporters, importing Empagliflozin from India to distribute it to other countries. Their order patterns are typically large and strategic, aiming to serve multiple markets efficiently.

5. Contract Manufacturers: Entities like GENERIC PHARMA S.A. in El Salvador may engage in contract manufacturing, importing active pharmaceutical ingredients (APIs) like Empagliflozin for formulation and packaging before distribution. Their purchasing behavior involves bulk procurement of APIs, followed by manufacturing processes to produce finished pharmaceutical products.

Understanding the import regulations for Empagliflozin in the top importing countries is crucial for market entry and compliance:

The demand for Empagliflozin in importing countries is driven by several factors:

1. Disease Prevalence: The rising incidence of type 2 diabetes globally has increased the need for effective management options like Empagliflozin. For instance, Mauritius reported a diabetes prevalence rate of approximately 22% in 2023, one of the highest globally, underscoring the demand for antidiabetic medications.

2. Government Healthcare Programs: Many countries have implemented national health programs focusing on non-communicable diseases, including diabetes. These programs often include the procurement of essential medicines like Empagliflozin to ensure widespread availability.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in countries like Sri Lanka and the UAE have led to increased access to medications, boosting the import and distribution of drugs such as Empagliflozin.

4. WHO Essential Medicines List Procurement: Empagliflozin's inclusion in the WHO Essential Medicines List has prompted countries to prioritize its procurement, ensuring that it is available in public healthcare facilities.

5. Tender-Based Purchasing: Government and large healthcare institutions often procure medications through tender processes, leading to bulk purchases of Empagliflozin. This approach ensures cost-effectiveness and consistent supply, contributing to the steady demand observed in the import data.

The presence of 236 buyers across 75 countries, as per TransData Nexus data, reflects a broad and sustained market opportunity for Empagliflozin, driven by these demand factors.